Actio Biosciences is a technology company.
Actio Biosciences is a technology company.
Actio Biosciences has raised $121.0M across 2 funding rounds.
Actio Biosciences has raised $121.0M in total across 2 funding rounds.
Actio Biosciences has raised $121.0M in total across 2 funding rounds.
Actio Biosciences's investors include Canaan Partners, Deerfield Management.
Actio Biosciences is a clinical-stage biotech company developing precision medicines that target shared genetic biology between rare and common diseases, using advances in genetics, bioinformatics, and drug discovery to de-risk targets and streamline development.[1][2][3] Its lead programs include ABS-0871, a TRPV4 inhibitor in Phase 1 for Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder, and ABS-1230, a KCNT1 inhibitor in preclinical stages for genetic epilepsies, with potential expansion to broader indications.[5][7] The company serves patients with high unmet needs in rare diseases while aiming to inform therapies for larger populations, backed by $55M Series A (2022) and $66M Series B financings from investors like Canaan, Droia Ventures, Deerfield, and EcoR1.[3][5]
Actio's platform features a proprietary Rare Disease Target Atlas and expertise in creating disease models, such as partnerships with The Jackson Laboratory for advanced mouse models, to validate targets before clinical stages.[3][6] This "rare-to-common" approach enhances success probabilities by starting with genetically defined rare populations.[1][4]
Actio Biosciences was founded in October 2021 in San Diego by leaders in genetics and drug development, including co-founder and CEO David Goldstein, Ph.D., formerly of Columbia University, and John McHutchison, AO, M.D., a co-founder and board member.[2][3][5] The idea emerged from recognizing that genetic insights from rare, monogenic diseases—like those enabled by sequencing—could de-risk drug targets for heterogeneous common diseases, addressing a key challenge in traditional discovery where success rates are low.[1][6]
Early traction came swiftly: the company launched publicly in 2022 with a $55M Series A to advance its TRPV4 program for CMT2C and initiate other efforts, including collaborations with The Jackson Laboratory for precise disease models.[3][6] A pivotal partnership with Jax stemmed from a call between Goldstein and Jax CEO Lon Cardon, both shifting from prior roles to prioritize Mendelian disease research.[6]
Actio stands out in precision medicine through:
Actio rides the wave of genetics-led drug discovery, fueled by post-sequencing advances in Mendelian diseases, where rare disorder insights unlock common disease biology amid moderating discovery rates in single-gene research.[1][6] Timing aligns with precision medicine's rise, as vast genetic data demands platforms to connect rare (homogenous) and common (heterogeneous) targets, de-risking amid high failure rates in traditional pharma.[2][3]
Market forces favor Actio: surging investor interest in biotech (evident in its $121M+ funding), unmet needs in rare diseases like CMT2C and KCNT1 epilepsy, and regulatory incentives for orphan drugs that enable broader labels.[3][5] It influences the ecosystem by pioneering "one-to-many" expansion, inspiring similar platforms and enhancing clinical success probabilities across biotech.[4]
Actio's near-term focus is advancing ABS-1230 into clinic for KCNT1 epilepsy and expanding ABS-0871 beyond Phase 1 into CMT2C and bladder indications, with preclinical pushes in genetic skin diseases and dysostoses.[5][7] Trends like AI-augmented genetics and better disease models will accelerate its pipeline, potentially yielding transformative therapies that bridge rare and common markets.
As Actio scales from its "one to many" foundation—leveraging genetics to restore disease-causing gene activity—its influence could redefine precision medicine, delivering higher-success drugs for patients long underserved.[1][2]
Actio Biosciences has raised $121.0M across 2 funding rounds. Most recently, it raised $66.0M Series B in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $66.0M Series B | Canaan Partners, Deerfield Management | |
| Sep 1, 2023 | $55.0M Series A | Canaan Partners, Deerfield Management |